NCT01891786

Brief Summary

The primary objective of the CORDIA study is to use an effective evidence-based self-management intervention (SMI) for type 2 diabetes, with and without a novel test to give a personalised genetic and lifestyle risk of coronary heart disease, to examine their capacity to reduce the risk of coronary heart disease (CHD) and improve diabetes management in primary care patients with type 2 diabetes. The effect of these interventions on clinical, behavioural and psychological outcomes will be investigated.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
211

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2013

Typical duration for not_applicable

Geographic Reach
1 country

10 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 28, 2013

Completed
3 days until next milestone

Study Start

First participant enrolled

July 1, 2013

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 3, 2013

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2016

Completed
Last Updated

August 4, 2016

Status Verified

August 1, 2016

Enrollment Period

2.9 years

First QC Date

June 28, 2013

Last Update Submit

August 3, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Coronary heart disease 10 year risk

    Coronary heart disease 10 year risk as assessed using the United Kingdon Prospective Diabetes Study (UKPDS) Risk Calculator

    12 months

Secondary Outcomes (3)

  • Psycho-social impact of the intervention

    12 months

  • Health behaviour impact of the intervention

    12 months

  • Impact of receiving genetic results

    6 months

Study Arms (3)

Usual Care

NO INTERVENTION

The participant's General practitioner (GP) practice and/or practice nurse will provide care as normal for their patient.

Group Self-Management Intervention (SMI)

ACTIVE COMPARATOR

Participants will be asked to attend a total of 4 SMI sessions delivered on a weekly basis.

Behavioral: Self-Management Intervention

SMI + Risk Results

ACTIVE COMPARATOR

The participant will provide a saliva sample for analysis. They will attend an appointment with their nurse to receive personalised results on their combined genetic and lifestyle risk for developing CHD in the next 10 years. They will then be asked to attend the 4 week SMI programme.

Behavioral: Self-Management InterventionBehavioral: Risk Result

Interventions

The SMI will incorporate a discussion to introduce self-management and why it is important, and about problems associated with reducing CHD risk and managing type 2 diabetes. Specific topics addressed will include health behaviours to reduce CHD risk and manage diabetes including diet and exercise, as well as behaviours specific to managing diabetes, including medication adherence and self-care behaviours (e.g. footcare). Sessions are patient-directed and employ a shared decision-making approach, such that participants work with one another and the practice nurse facilitator to identify specific problems that they wish to address, and to identify solutions and approaches to managing their diabetes and CHD risk

Group Self-Management Intervention (SMI)SMI + Risk Results
Risk ResultBEHAVIORAL

Participants will receive in-person personalised feedback about their combined genetic and lifestyle 10 year risk for developing CHD.

SMI + Risk Results

Eligibility Criteria

Age25 Years - 74 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Males and females aged 25-70 years diagnosed with type 2 diabetes
  • White, Afro-Caribbean or Asian-Indian ethnicity
  • Most previous or baseline HbA1c ≥6.5% or 48 mmol/mol
  • Fluency in written and spoken English

You may not qualify if:

  • Diagnosis of ischemic heart disease, stroke, Transient Ischaemic Attack (TIA) or peripheral vascular disease
  • Serious or enduring mental health problems that would prevent the patient from completing the study
  • Currently receiving treatment for a life-threatening condition (e.g., cancer) or in the terminal stages of a condition
  • Adults who cannot consent for themselves

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (10)

Addison House Surgery

Harlow, Essex, CM20 1DS, United Kingdom

Location

Church Street Surgery

Ware, Essex, SG12 9EG, United Kingdom

Location

Dolphin House Surgery

Ware, Essex, SG12 9HJ, United Kingdom

Location

Wallace House Surgery

Hertford, Hertfordshire, SG14 1HZ, United Kingdom

Location

Cambridgeshire Community Services NHS Trust

Cambridgeshire, PE27 4LG, United Kingdom

Location

Chesterfield Drive Surgery

Ipswich, IP1 6DW, United Kingdom

Location

Martlesham health Surgery

Ipswich, IP5 3SL, United Kingdom

Location

Dr Taylor and Partners

Woodbridge Suffolk, IP12 1EE, United Kingdom

Location

The Peninsula Practice

Woodbridge Suffolk, IP12 2NN, United Kingdom

Location

Wickham Market Medical Centre

Woodbridge Suffolk, IP13 0SB, United Kingdom

Location

Related Publications (2)

  • Beaney KE, Ward CE, Bappa DA, McGale N, Davies AK, Hirani SP, Li K, Howard P, Vance DR, Crockard MA, Lamont JV, Newman S, Humphries SE. A 19-SNP coronary heart disease gene score profile in subjects with type 2 diabetes: the coronary heart disease risk in type 2 diabetes (CoRDia study) study baseline characteristics. Cardiovasc Diabetol. 2016 Oct 3;15(1):141. doi: 10.1186/s12933-016-0457-7.

  • Davies AK, McGale N, Humphries SE, Hirani SP, Beaney KE, Bappa DA, McCabe JG, Newman SP. Effectiveness of a self-management intervention with personalised genetic and lifestyle-related risk information on coronary heart disease and diabetes-related risk in type 2 diabetes (CoRDia): study protocol for a randomised controlled trial. Trials. 2015 Dec 2;16:547. doi: 10.1186/s13063-015-1073-7.

MeSH Terms

Conditions

Coronary DiseaseDiabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Stanton P Newman, PhD

    City, University of London

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

June 28, 2013

First Posted

July 3, 2013

Study Start

July 1, 2013

Primary Completion

June 1, 2016

Study Completion

June 1, 2016

Last Updated

August 4, 2016

Record last verified: 2016-08

Data Sharing

IPD Sharing
Will not share

Locations